Atossa Therapeutics
ATOS
67 hedge funds and large institutions have $34.7M invested in Atossa Therapeutics in 2024 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 5 closing their positions.
360% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 5
334% more capital inflows, than outflows
Capital inflows: $4.76M | Capital outflows: $1.1M
146% more call options, than puts
Call options by funds: $480K | Put options by funds: $195K
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
37% more funds holding
Funds holding: 49 → 67 (+18)
2.64% more ownership
Funds ownership: 12.75% → 15.39% (+2.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.03M |
| 2 |
Morgan Stanley
New York
|
+$697K |
| 3 |
Goldman Sachs
New York
|
+$673K |
| 4 |
HRT Financial
New York
|
+$312K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$266K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$395K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$360K |
| 3 |
Two Sigma Investments
New York
|
-$137K |
| 4 |
XTX Topco
George Town,
Cayman Islands
|
-$75.1K |
| 5 |
BlackRock
New York
|
-$48.4K |
ATOS Hedge Fund Activity: Q1 2024 in Review
67 of the 6,963 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q1 2024, worth a combined $34.7M — up 146% from $14.1M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ATOS positions and 5 closed out — a net gain of 18 holders — while 13 added to existing stakes and 9 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.03M. The largest seller was GSA Capital Partners, exiting entirely with an estimated $395K sold.
- 67 institutional investors held Atossa Therapeutics (ATOS) as of Q1 2024, up from 49 in Q4 2023.
- Funds reported $34.7M of Atossa Therapeutics stock for Q1 2024, up 146% quarter-over-quarter.
- 23 funds opened new Atossa Therapeutics positions in Q1 2024 and 5 closed out, a net change of +18 holders.
- The largest Atossa Therapeutics buyer in Q1 2024 was Millennium Management, an estimated $1.03M added.
- The largest Atossa Therapeutics seller in Q1 2024 was GSA Capital Partners, an estimated $395K sold.
Based on aggregated 13F filings for Q1 2024.